[({5-hydroxy-2-[(1-{4’-[(2S)-2-hydroxypropyl]biphenyl-4-yl}piperidin-4-yl)methyl]-6-methylpyrimidin-4-yl}carbonyl)amino]acetic acid | 1296273-51-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [({5-hydroxy-2-[(1-{4’-[(2S)-2-hydroxypropyl]biphenyl-4-yl}piperidin-4-yl)methyl]-6-methylpyrimidin-4-yl}carbonyl)amino]acetic acid
• 英文别名: [({5-hydroxy-2-[(1-{4'-[(2S)-2-hydroxypropyl]biphenyl-4-yl}piperidin-4-yl)methyl]-6-methylpyrimidin-4-yl}carbonyl)amino]acetic acid；2-[[5-hydroxy-2-[[1-[4-[4-[(2S)-2-hydroxypropyl]phenyl]phenyl]piperidin-4-yl]methyl]-6-methylpyrimidine-4-carbonyl]amino]acetic acid
• CAS: 1296273-51-2
• 化学式: C₂₉H₃₄N₄O₅
• 分子量: 518.613
• InChiKey: INUWXIVLFZLXDW-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE
  申请人：Kuribayashi Takeshi

  公开号：US20120220609A1

  公开（公告）日：2012-08-30

  The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R 1 : formula (1A): [wherein, R 4 and R 5 : H, halogen, or alkyl; R 6 : H, halogen, alkyl, or the like; R 7 : substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q 1 : a monocyclic heterocyclic group; ring Q 2 : a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q 3 : a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R 2 : alkyl, or methylsulfanyl; and R 3 : H, or methyl], or the like.

  本发明提供了一种增强促红细胞生成素产生的化合物。本发明提供了一种由式(1)表示的化合物：[其中，R1：式(1A)：[其中，R4和R5：H、卤素或烷基；R6：H、卤素、烷基或类似物；R7：可替代的羟基烷基、可替代的羟基卤代烷基、可替代的烷氧基烷基或类似物；取代基α：酮基、羟基、氨基或类似物；环Q1：单环杂环基团；环Q2：单环碳氢环基团，或单环杂环基团；环Q3：单环碳氢环基团，或单环杂环基团；X：单键，亚甲基，乙烯基或类似物]；R2：烷基，或甲硫基；R3：H，或甲基]，或类似物。
• WOUND TREATMENT AGENT
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3391887A1

  公开（公告）日：2018-10-24

  The present invention provides a therapeutic agent for a wound comprising a compound represented by the formula (I) wherein R1 represents a hydroxy C1-C6 alkyl group, a C2-C7 alkanoyl group, a C2-C7 alkanoyl C1-C6 alkyl group, a (C1-C6 alkoxy)carbonyl group, a (C1-C6 alkoxy)carbonyl C1-C6 alkyl group, a carboxy group, or a carboxy C1-C6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.

  本发明提供了一种伤口治疗剂，其活性成分包含由式（I）代表的化合物，其中 R1 代表羟基 C1-C6 烷基、C2-C7 烷酰基、C2-C7 烷酰基 C1-C6 烷基、(C1-C6 烷氧基)羰基、(C1-C6 烷氧基)羰基 C1-C6 烷基、羧基或羧基 C1-C6 烷基或其药理学上可接受的盐。
• DRUG FOR PREVENTING OR TREATING LACTIC ACIDOSIS
  申请人：Keio University

  公开号：EP3441070A1

  公开（公告）日：2019-02-13

  An object is to provide a pharmaceutical composition containing a compound having an excellent effect of preventing or treating lactic acidosis. Provided is a pharmaceutical composition for preventing or treating lactic acidosis, including, as an active ingredient, a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof: in the general formula (I), R1 represents a hydroxy C1 to C6 alkyl group, a C2 to C7 alkanoyl group, a C2 to C7 alkanoyl C1 to C6 alkyl group, a (C1 to C6 alkoxy) carbonyl group, a (C1 to C6 alkoxy) carbonyl C1 to C6 alkyl group, a carboxy group, or a carboxy C1 to C6 alkyl group.

  目的是提供一种药物组合物，其中含有对预防或治疗乳酸性酸中毒具有良好效果的化合物。本发明提供了一种用于预防或治疗乳酸性酸中毒的药物组合物，其活性成分包括通式（I）代表的化合物或其药理学上可接受的盐： 在通式（I）中，R1 代表羟基 C1 至 C6 烷基、C2 至 C7 烷酰基、C2 至 C7 烷酰基 C1 至 C6 烷基、(C1 至 C6 烷氧基)羰基、(C1 至 C6 烷氧基)羰基 C1 至 C6 烷基、羧基或羧基 C1 至 C6 烷基。
• EP3756671A1
  申请人：——

  公开号：EP3756671A1

  公开（公告）日：2020-12-30
• THERAPEUTIC AGENT FOR A WOUND
  申请人：DAIICHI SANKYO COMPANY LIMITED

  公开号：US20190000847A1

  公开（公告）日：2019-01-03

  The present invention provides a therapeutic agent for a wound comprising a compound represented by the formula (I) wherein R 1 represents a hydroxy C 1 -C 6 alkyl group, a C 2 -C 7 alkanoyl group, a C 2 -C 7 alkanoyl C 1 -C 6 alkyl group, a (C 1 -C 6 alkoxy)carbonyl group, a (C 1 -C 6 alkoxy)carbonyl C 1 -C 6 alkyl group, a carboxy group, or a carboxy C 1 -C 6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.